Novocure Announces Preliminary Fourth Quarter and Full Year 2016 Operating Statistics
January 10 2017 - 7:00AM
Business Wire
1,091 active patients at Dec. 31, 2016, an
increase of 80 percent versus Dec. 31, 2015
Novocure (NASDAQ:NVCR), a commercial-stage oncology company
developing a proprietary therapy for solid tumors, will provide a
business update as well as its preliminary operating statistics for
the fourth quarter and full year 2016 at the 35th Annual J.P.
Morgan Healthcare Conference on Jan. 11, 2017 in San Francisco.
“The fourth quarter of 2016 was the eighth consecutive quarter
of active patient growth for Novocure since the presentation of our
successful EF-14 phase 3 pivotal trial data in newly diagnosed
glioblastoma (GBM),” said Asaf Danziger, Novocure’s Chief Executive
Officer. “As of Dec. 31, 2016, we had nearly 1,100 active patients
on treatment, including 256 patients in EMEA, reflecting the
increasing importance of our non-U.S. markets.”
Mr. Danziger continued, “The fourth quarter of 2016 was also
marked by significant clinical milestones. A long-term analysis of
the EF-14 data, presented at the 21st Annual Scientific Meeting of
the Society for Neuro-Oncology in November, demonstrated a 70
percent improvement in survival rate at four years for patients
treated with Optune together with temozolomide compared to patients
treated with temozolomide alone. During our R&D day, we also
shared topline results from phase 2 pilot studies in advanced
pancreatic cancer, recurrent ovarian cancer and mesothelioma,
suggesting that Tumor Treating Fields, when added to standard of
care treatments, may improve patient outcomes.” *
Fourth Quarter and Full Year 2016 Operating
Statistics
- There were 1,091 active patients on
Optune therapy on Dec. 31, 2016, an increase of 80 percent versus
Dec. 31, 2015. Of the active patients, 835 were in the U.S. and 256
were in Novocure’s EMEA markets.
- 706 prescriptions were received in the
fourth quarter of 2016, an increase of 27 percent versus the fourth
quarter of 2015. 544 of the prescriptions were received in the U.S.
and 162 were received outside of the U.S., primarily in
Europe.
- 2,808 prescriptions were received in
2016, an increase of 58 percent versus 2015. Of the prescriptions,
2,344 were received in the U.S. and 464 were received outside of
the U.S., primarily in Europe.
* TTFields are not approved for the treatment of pancreatic
cancer, recurrent ovarian cancer or mesothelioma. Their safety and
effectiveness in these indications has not been established.
About Novocure
Novocure is a commercial-stage oncology company developing a
proprietary therapy called Tumor Treating Fields, or TTFields, for
the treatment of solid tumor cancers. Novocure’s commercialized
product, Optune, is approved for the treatment of adult patients
with glioblastoma. Novocure has ongoing or completed phase 2 pilot
trials investigating TTFields in non-small cell lung cancer,
pancreatic cancer, ovarian cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in
Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York
City. Additionally, the company has offices in Germany, Switzerland
and Japan, and a research center in Haifa, Israel. For additional
information about the company, please visit www.novocure.com or
follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, development of potential products,
interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market
prospects for its products, and other statements regarding matters
that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements
such as “anticipate,” “estimate,” “expect,” “project,” “intend,”
“plan,” “believe” or other words and terms of similar meaning.
Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, regulatory and political
conditions as well as more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on March 1, 2016, with the U.S. Securities and Exchange
Commission. Given these risks and uncertainties, any or all of
these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Novocure does not intend
to update publicly any forward-looking statement, except as
required by law. Any forward-looking statements herein speak only
as of the date hereof. The Private Securities Litigation Reform Act
of 1995 permits this discussion.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170110005471/en/
NovocureMedia and Investor ContactAshley Cordova,
212-767-7558acordova@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024